[HTML][HTML] Effect of mRNA vaccine boosters against SARS-CoV-2 Omicron infection in Qatar
…, HE Al-Romaihi, MH Al-Thani, A Al-Khal… - … England Journal of …, 2022 - Mass Medical Soc
Background Waning of vaccine protection against coronavirus disease 2019 (Covid-19)
and the emergence of the omicron (or B.1.1.529) variant of the severe acute respiratory …
and the emergence of the omicron (or B.1.1.529) variant of the severe acute respiratory …
[HTML][HTML] mRNA-1273 COVID-19 vaccine effectiveness against the B. 1.1. 7 and B. 1.351 variants and severe COVID-19 disease in Qatar
…, HE Al Romaihi, MH Al-Thani, A Al Khal… - Nature medicine, 2021 - nature.com
The SARS-CoV-2 pandemic continues to be a global health concern. The mRNA-1273 (Moderna)
vaccine was reported to have an efficacy of 94.1% at preventing symptomatic COVID-…
vaccine was reported to have an efficacy of 94.1% at preventing symptomatic COVID-…
[HTML][HTML] Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA. 1 and BA. 2 subvariants in Qatar
…, HE Al-Romaihi, MH Al-Thani, A Al-Khal… - Nature …, 2022 - nature.com
SARS-CoV-2 Omicron BA.1 and BA.2 subvariants are genetically divergent. We conducted
a matched, test-negative, case-control study to estimate duration of protection of the second …
a matched, test-negative, case-control study to estimate duration of protection of the second …
[HTML][HTML] BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar
…, HE Al Romaihi, AA Butt, MH Al-Thani, A Al Khal… - Nature medicine, 2021 - nature.com
With the global expansion of the highly transmissible SARS-CoV-2 Delta (B.1.617.2) variant,
we conducted a matched test-negative case–control study to assess the real-world …
we conducted a matched test-negative case–control study to assess the real-world …
[HTML][HTML] SARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95% efficacy
…, HE Al Romaihi, MH Al-Thani, A Al Khal… - …, 2021 - thelancet.com
Background Reinfection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
has been documented, raising public health concerns. SARS-CoV-2 reinfections were …
has been documented, raising public health concerns. SARS-CoV-2 reinfections were …
Assessment of the risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) reinfection in an intense reexposure setting
…, MG Al Kuwari, HE Al Romaihi… - Clinical Infectious …, 2021 - academic.oup.com
Background Risk of reinfection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
is unknown. We assessed the risk and incidence rate of documented SARS-CoV-2 …
is unknown. We assessed the risk and incidence rate of documented SARS-CoV-2 …
Duration of immune protection of SARS-CoV-2 natural infection against reinfection
…, HE Al-Romaihi, MH Al-Thani, A Al-Khal… - Journal of Travel …, 2022 - academic.oup.com
Background The future of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
pandemic hinges on virus evolution and duration of immune protection of natural infection …
pandemic hinges on virus evolution and duration of immune protection of natural infection …
Association of prior SARS-CoV-2 infection with risk of breakthrough infection following mRNA vaccination in Qatar
…, AA Butt, HE Al Romaihi, MH Al-Thani, A Al Khal… - Jama, 2021 - jamanetwork.com
Importance The effect of prior SARS-CoV-2 infection on vaccine protection remains poorly
understood. Objective To assess protection from SARS-CoV-2 breakthrough infection after …
understood. Objective To assess protection from SARS-CoV-2 breakthrough infection after …
[HTML][HTML] Long-term COVID-19 booster effectiveness by infection history and clinical vulnerability and immune imprinting: a retrospective population-based cohort study
…, HE Al-Romaihi, MH Al-Thani, A Al-Khal… - The Lancet Infectious …, 2023 - thelancet.com
Background Long-term effectiveness of COVID-19 mRNA boosters in populations with different
previous infection histories and clinical vulnerability profiles is inadequately understood. …
previous infection histories and clinical vulnerability profiles is inadequately understood. …
[HTML][HTML] … from previous natural infection compared with mRNA vaccination against SARS-CoV-2 infection and severe COVID-19 in Qatar: a retrospective cohort study
…, AA Butt, HE Al-Romaihi, MH Al-Thani, A Al-Khal… - The Lancet …, 2022 - thelancet.com
Background Understanding protection conferred by natural SARS-CoV-2 infection versus
COVID-19 vaccination is important for informing vaccine mandate decisions. We compared …
COVID-19 vaccination is important for informing vaccine mandate decisions. We compared …
